NMRA
Neumora Therapeutics, Inc. Common Stock NASDAQ Listed Sep 15, 2023$1.51
-1.31%
vs $1.53
Mkt Cap $246.7M
52w Low $0.73
27.2% of range
52w High $3.59
50d MA $1.93
200d MA $2.19
P/E (TTM)
-1.0x
EV/EBITDA
—
P/B
2.4x
Debt/Equity
0.0x
ROE
-228.1%
P/FCF
-1.2x
RSI (14)
41.80
ATR (14)
$0.17
Beta
3.12
50d MA
$1.93
200d MA
$2.19
Avg Volume
2.8M
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
490 Arsenal Way · Watertown, DE 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | BMO | -0.34 | -0.35 | -2.9% | 2.87 | +0.7% | -1.4% | -6.7% | -2.7% | -2.3% | -1.6% | — |
| Nov 6, 2025 | BMO | -0.34 | -0.35 | -2.9% | 2.58 | -3.1% | -0.8% | +9.8% | -2.1% | +4.0% | -5.9% | — |
| Aug 6, 2025 | BMO | -0.38 | -0.33 | +13.2% | 1.59 | +4.4% | +3.8% | -11.5% | -1.4% | +4.2% | +4.0% | — |
| May 12, 2025 | BMO | -0.40 | -0.42 | -5.0% | 0.69 | -0.2% | -1.9% | -9.5% | +8.2% | +5.4% | -1.6% | — |
| Mar 3, 2025 | BMO | -0.46 | -0.37 | +19.6% | 1.41 | -2.8% | +0.0% | +1.4% | +6.3% | -2.0% | -10.1% | — |
| Nov 12, 2024 | BMO | -0.38 | -0.45 | -18.4% | 11.31 | +1.5% | -4.7% | +8.4% | -7.3% | -9.2% | +0.2% | — |
| Aug 6, 2024 | BMO | -0.37 | -0.37 | +0.0% | 11.99 | -0.3% | -1.7% | -4.7% | +0.2% | -0.9% | +1.3% | — |
| May 7, 2024 | BMO | -0.35 | -0.34 | +2.9% | 9.81 | -2.1% | -4.0% | +3.7% | -5.9% | -2.5% | +6.9% | — |
| Mar 7, 2024 | BMO | -0.65 | -0.71 | -9.2% | 19.00 | +3.3% | -5.3% | +0.3% | -3.9% | -14.6% | +2.2% | — |
| Nov 1, 2023 | BMO | -0.36 | -1.14 | -216.7% | 10.79 | -0.4% | +1.2% | +8.5% | -3.7% | +1.7% | -8.4% | — |
| Jun 30, 2023 | BMO | — | -0.25 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | BMO | — | -0.23 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 16 | H.C. Wainwright | Reiterates | Buy | $7 | $0.91 | $0.95 | +3.9% | +70.6% | -1.9% | -1.3% | — | — |
| Jun 16 | Needham | Reiterates | Buy | $5 | $0.91 | $0.95 | +3.9% | +70.6% | -1.9% | -1.3% | — | — |
| Mar 31 | Guggenheim | Maintains | Buy → Buy | — | $1.93 | $1.91 | -1.0% | +1.0% | +7.2% | -4.3% | +6.0% | +0.5% |
| Mar 31 | Needham | Maintains | Buy → Buy | — | $1.93 | $1.91 | -1.0% | +1.0% | +7.2% | -4.3% | +6.0% | +0.5% |
| Feb 17 | William Blair | Upgrade | Market Perform → Outperform | — | $3.20 | $3.35 | +4.7% | +10.6% | +1.4% | -3.1% | -2.6% | +1.8% |
| Dec 1 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $2.24 | $2.53 | +12.9% | +8.0% | -7.9% | +1.8% | +0.4% | -2.6% |
| Nov 17 | Stifel | Maintains | Hold → Hold | — | $2.65 | $2.62 | -1.1% | -2.3% | +2.7% | -4.5% | -7.1% | -1.3% |
| Oct 28 | Needham | Maintains | Buy → Buy | — | $2.69 | $2.70 | +0.4% | -3.7% | -3.5% | +17.2% | +3.1% | -0.3% |
| Oct 27 | Guggenheim | Upgrade | Neutral → Buy | — | $2.63 | $2.68 | +1.9% | +2.3% | -3.7% | -3.5% | +17.2% | +3.1% |
| Sep 16 | JP Morgan | Downgrade | Neutral → Underweight | — | $1.52 | $1.50 | -1.3% | -1.3% | -3.3% | +8.3% | +12.1% | -1.7% |
| Jul 16 | Mizuho | Maintains | Outperform → Outperform | — | $1.45 | $1.53 | +5.5% | -3.4% | +22.1% | +8.2% | +5.9% | -3.6% |
| May 13 | Needham | Maintains | Buy → Buy | — | $0.69 | $0.69 | -0.2% | -1.9% | -9.5% | +8.2% | +5.4% | -1.6% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $0.76 | $0.72 | -4.7% | -5.2% | -4.9% | -1.8% | -2.1% | -4.0% |
| Apr 2 | BofA Securities | Downgrade | Buy → Underperform | — | $0.91 | $0.89 | -2.6% | +3.0% | -9.7% | -13.3% | +2.3% | -3.9% |
| Mar 10 | Guggenheim | Downgrade | Buy → Neutral | — | $1.49 | $1.43 | -4.0% | -10.1% | +6.7% | -3.5% | +1.4% | -8.6% |
| Mar 7 | Stifel | Downgrade | Buy → Hold | — | $1.52 | $1.32 | -13.2% | -2.0% | -10.1% | +6.7% | -3.5% | +1.4% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.32 | -13.2% | -2.0% | -10.1% | +6.7% | -3.5% | +1.4% |
| Mar 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $1.41 | $1.37 | -2.8% | +0.0% | +1.4% | +6.3% | -2.0% | -10.1% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.41 | $1.37 | -2.8% | +0.0% | +1.4% | +6.3% | -2.0% | -10.1% |
| Mar 4 | Needham | Maintains | Buy → Buy | — | $1.41 | $1.37 | -2.8% | +0.0% | +1.4% | +6.3% | -2.0% | -10.1% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.69 | $1.72 | +1.8% | +3.0% | -0.6% | -4.0% | +3.0% | +5.3% |
| Jan 6 | BofA Securities | Maintains | Buy → Buy | — | $2.17 | $2.24 | +3.2% | +14.3% | +4.0% | -8.1% | -6.8% | +9.5% |
| Jan 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.97 | $2.23 | +13.2% | +10.2% | +14.3% | +4.0% | -8.1% | -6.8% |
| Jan 2 | Needham | Maintains | Buy → Buy | — | $10.60 | $1.88 | -82.3% | -81.4% | +10.2% | +14.3% | +4.0% | -8.1% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.32 | $10.40 | +0.8% | +5.3% | +0.0% | -6.3% | +3.1% | +3.3% |
| Nov 22 | RBC Capital | Maintains | Outperform → Outperform | — | $9.69 | $9.79 | +1.0% | +0.5% | -0.7% | +1.0% | -0.1% | +1.8% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $11.31 | $11.48 | +1.5% | -4.7% | +8.4% | -7.3% | -9.2% | +0.2% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.31 | $11.48 | +1.5% | -4.7% | +8.4% | -7.3% | -9.2% | +0.2% |
| Nov 5 | JP Morgan | Downgrade | Overweight → Neutral | — | $11.71 | $11.02 | -5.9% | +1.7% | +6.7% | +2.4% | +4.0% | +0.7% |
| Oct 18 | Needham | Maintains | Buy → Buy | — | $16.96 | $17.00 | +0.2% | -2.8% | -14.8% | -0.6% | -4.7% | -2.3% |
| Sep 12 | Needham | Maintains | Buy → Buy | — | $11.40 | $11.50 | +0.9% | +3.8% | +1.7% | -0.7% | -1.8% | +4.1% |
| Sep 4 | RBC Capital | Maintains | Outperform → Outperform | — | $10.74 | $10.74 | +0.0% | +2.3% | -1.8% | -3.1% | +9.1% | -1.1% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $11.99 | $11.95 | -0.3% | -1.7% | -4.7% | +0.2% | -0.9% | +1.3% |
| Mar 28 | RBC Capital | Maintains | Outperform → Outperform | — | $12.61 | $12.98 | +2.9% | +9.0% | +1.4% | -1.2% | -3.4% | +3.2% |
| Mar 18 | JP Morgan | Maintains | Overweight → Overweight | — | $15.09 | $14.98 | -0.7% | -6.2% | -0.9% | -0.3% | -0.1% | -5.5% |
| Mar 8 | RBC Capital | Maintains | Outperform → Outperform | — | $19.00 | $19.63 | +3.3% | -5.3% | +0.3% | -3.9% | -14.6% | +2.2% |
| Nov 8 | JP Morgan | Maintains | Overweight → Overweight | — | $11.60 | $12.09 | +4.2% | -8.4% | -0.3% | +9.2% | +3.3% | -0.8% |
No insider trades available.
8-K · 1.01
!! High
Neumora Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Jun 15
8-K · 2.02
!! High
Neumora Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Neumora Therapeutics reported Q1 2026 financial results, providing investors with updated operational metrics and financial performance for the quarter ending March 31, 2026.
May 7
8-K
Unknown — 8-K Filing
Neumora's clinical-stage pipeline and cash position updates will clarify runway for drug development and whether the company can reach key milestones before requiring additional financing, directly impacting dilution risk.
Mar 30
8-K · 7.01
! Medium
Neumora Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Neumora Therapeutics (NMRA) disclosed a presentation through Regulation FD, providing investors with updated information about the company's business and strategy.
Feb 11
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Softbank Group Corp. | 6,090,301 | $12M | Reduced | Mar 2026 |
| 2 | Mic Capital Management Uk Llp | 4,460,700 | $9M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 3,891,893 | $8M | New | Mar 2026 |
| 4 | Fmr Llc | 3,498,658 | $7M | — | Mar 2026 |
| 5 | Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | 3,309,123 | $6M | — | Mar 2026 |
| 6 | Millennium Management | 2,754,854 | $5M | Reduced | Mar 2026 |
| 7 | Iconiq Capital, Llc | 2,559,090 | $5M | — | Mar 2026 |
| 8 | Lunate Capital Ltd | 2,124,143 | $4M | — | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 2,036,692 | $4M | Added | Mar 2026 |
| 10 | Johnson & Johnson | 1,849,445 | $4M | — | Mar 2026 |
| 11 | Renaissance Technologies Llc | 1,388,998 | $3M | Reduced | Mar 2026 |
| 12 | Susquehanna International Group, Llp | 1,240,241 | $2M | Added | Mar 2026 |
| 13 | Marshall Wace, Llp | 1,195,310 | $2M | Added | Mar 2026 |
| 14 | Jane Street Group, Llc | 1,128,972 | $2M | Added | Dec 2025 |
| 15 | Tang Capital Management Llc | 967,235 | $2M | Reduced | Dec 2025 |
| 16 | Tudor Investment Corp | 771,418 | $2M | New | Mar 2026 |
| 17 | Point72 Asset Management | 602,403 | $1M | Reduced | Mar 2026 |
| 18 | Franklin Resources Inc | 511,084 | $997K | New | Mar 2026 |
| 19 | Morgan Stanley | 476,968 | $854K | Reduced | Dec 2025 |
| 20 | Acadian Asset Management Llc | 381,494 | $738K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$246.7M
Enterprise Value
$64.4M
P/E (TTM)
-1.04x
Forward P/E
—
PEG Ratio
0.24x
P/B
2.38x
P/S
—
P/FCF
-1.20x
EV/EBITDA
—
Shares Out
163.4M
Financials (TTM)
Revenue
$0
Net Income
-$236.9M
EBITDA
-$233.4M
Free Cash Flow
-$206.4M
Op Cash Flow
-$206.4M
EPS Basic
$-1.45
EPS Diluted
$-1.45
EPS Forward
$-0.98
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$191.0M
Total Liab.
$87.2M
Total Equity
$103.9M
Cash
$182.5M
LT Debt
$193K
Book Value/Sh
$0.64
Debt/Equity
0.00x
Current Ratio
5.87
Quick Ratio
5.87
Returns & Growth
ROE
-228.1%
ROA
-124.0%
ROIC
-151.8%
Rev Growth YoY
+0.0%
EPS Growth YoY
+5.2%
Price Returns
2W
-6.1%
1M
-25.1%
3M
-47.0%
6M
-17.4%
12M
+158.3%
Technicals
52W High
$3.59
52W Low
$0.73
50d MA
$1.93
200d MA
$2.19
RSI (14)
41.80
ATR (14)
$0.17
Beta
3.12
Avg Volume
2.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$7.00
High
$8.00
Low
$6.00
Median
$7.00
Data updated apr 26, 2026 3:20pm
· Source: financialmodelingprep.com